Tag: Erytech
Pherecydes Pharma / Erytech: the TC of Lyon dismisses Akkadian
By Alexandra Saintpierre Published on 06/14/2023 at 9:38 p.m. Photo credit © Erytech (Boursier.com) — The biotechnology company…
Erytech: Akkadian Partners accuses managers of liquidation blackmail – 06/13/2023 at 11:26
(AOF) – Akkadian Partners “says no to the liquidation of Erytech in the event of failure of the merger with Pherecydes”. “It’s a scandal” continues the activist fund, to impose…
Erytech: defends the Pherecydes project, accuses Akkadian – 06/12/2023 at 14:30
(CercleFinance.com) – Erytech on Monday accused the Akkadian investment fund of conducting a disinformation campaign against it by contesting its proposed merger with Pherecydes on the basis in particular of…
Erytech: Akkadian offers an alternative strategy – 06/07/2023 at 14:39
(CercleFinance.com) – The investment fund Akkadian Partners pleaded on Wednesday for an alternative strategy for Erytech, considering that the proposed merger with Pherecydes underestimated the value of biotech. Akkadian believes…
Pherecydes announces that legal proceedings have been initiated against Erytech by Akkadian to obtain the postponement of the vote on the merger with Pherecydes – 06/05/2023 at 08:00
Nantes, June 5, 2023 – 8:00 a.m. CEST – Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotechnology company specializing in phage therapy intended to treat antibiotic-resistant and/or complicated bacterial…
ERYTECH announces that Akkadian has initiated a procedure aimed at obtaining the postponement of the vote on the merger with Pherecydes – 06/05/2023 at 08:00
PRESS RELEASE ERYTECH announces that Akkadian has initiated a procedure to obtain the postponement of the vote of the merger with Pherecydes Lyon (France), June 5, 2023 – ERYTECH Pharma…
ERYTECH announces that Akkadian has initiated a procedure aimed at obtaining the postponement of the vote on the merger with Pherecydes – 06/05/2023 at 08:00
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected] ERYTECH Pharma (Euronext Paris and…
ERYTECH announces the procedures for making available the preparatory documents for the Combined General Meeting of June 23, 2023 – 05/24/2023 at 10:05 p.m.
ERYTECH announces the terms of provision preparatory documents for the Combined General Meeting of June 23, 2023 Lyon (France), and Cambridge, MA (US) May 24, 2023 – ERYTECH Pharma (Euronext…
ERYTECH announces the procedures for making available the preparatory documents for the Combined General Meeting of June 23, 2023 – 05/24/2023 at 10:05 p.m.
Lyon (France), and Cambridge, MA (US) May 24, 2023 – ERYTECH Pharma (Euronext & Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drugs in red blood cells…
ERYTECH announces the availability of the exemption document relating to the proposed merger with Pherecydes – 05/23/2023 at 22:05
Lyon (France), May 23, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells, announces that…
Erytech: the Akkadian Partners fund denounces an “abuse of power” by managers – 05/19/2023 at 11:09
(AOF) – Akkadian Partners, new shareholder of Erytech and opponent of the merger of biotech with the company Pherecydes, denounces in a press release published today a “characterised abuse of…
ERYTECH provides an update on its activities and publishes its results for the fourth quarter and the full year 2022 – 03/23/2023 at 22:05
Announcement of the combination with Pherecydes with the aim of creating a world leader in extended phage therapy targeting antibiotic-resistant pathogenic bacteria Implementation of a deep restructuring that…